TY - JOUR
T1 - Discordant genotype-phenotype correlation in familial hyperaldosteronism type III with KCNJ5 gene mutation
T2 - A patient report and review of the literature
AU - Adachi, Masanori
AU - Muroya, Koji
AU - Asakura, Yumi
AU - Sugiyama, Kenji
AU - Homma, Keiko
AU - Hasegawa, Tomonobu
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Background: Familial hyperaldosteronism type III (FH-III) is a rare autosomal dominant disease for which five missense mutations in KCNJ5 have been identified. FH-III has a wide phenotypic variability from spironolactone-responsive hyperaldosteronism to massive adrenal hypertrophy with drug-resistant hypertension. This variation has mainly been attributed to genotype, because, in contrast to other genotypes (G151R, T158A, I157S, and Y152C), (1) FH-III patients with G151E have shown milder phenotype, and (2) G151E-harboring cells were found to have rapid lethality due to much larger sodium conductance of the encoded channel (Kir3.4), which prevents adrenal hypertrophy. Methods: Here we describe the clinical course of a sporadic case of FH-III, with de novo G151R mutation. Results: The patient developed polyuria at around 1.5 years of age and developed hypertension and hypokalemia by 4 years of age. Thereafter, spironolactone treatment successfully ameliorated hyperaldosteronism for 7 years with no discernible adrenal enlargement. Conclusion: Diverse clinical severity in FH-III cannot be defined solely by KCNJ5 genotype.
AB - Background: Familial hyperaldosteronism type III (FH-III) is a rare autosomal dominant disease for which five missense mutations in KCNJ5 have been identified. FH-III has a wide phenotypic variability from spironolactone-responsive hyperaldosteronism to massive adrenal hypertrophy with drug-resistant hypertension. This variation has mainly been attributed to genotype, because, in contrast to other genotypes (G151R, T158A, I157S, and Y152C), (1) FH-III patients with G151E have shown milder phenotype, and (2) G151E-harboring cells were found to have rapid lethality due to much larger sodium conductance of the encoded channel (Kir3.4), which prevents adrenal hypertrophy. Methods: Here we describe the clinical course of a sporadic case of FH-III, with de novo G151R mutation. Results: The patient developed polyuria at around 1.5 years of age and developed hypertension and hypokalemia by 4 years of age. Thereafter, spironolactone treatment successfully ameliorated hyperaldosteronism for 7 years with no discernible adrenal enlargement. Conclusion: Diverse clinical severity in FH-III cannot be defined solely by KCNJ5 genotype.
KW - Endocrine hypertension
KW - Familial hyperaldosteronism
KW - KCNJ5
KW - Kir3.4
KW - Primary aldosteronism
UR - http://www.scopus.com/inward/record.url?scp=84928162344&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928162344&partnerID=8YFLogxK
U2 - 10.1159/000358197
DO - 10.1159/000358197
M3 - Article
C2 - 24819081
AN - SCOPUS:84928162344
SN - 1663-2818
VL - 82
SP - 138
EP - 142
JO - Hormone Research in Paediatrics
JF - Hormone Research in Paediatrics
IS - 2
ER -